FHLC vs XLV

Key Takeaways

• FHLC tracks a broad MSCI index covering the full U.S. health care sector including small- and mid-cap stocks, while XLV follows a narrower S&P 500-based index limited to large-cap health care companies.
• Both ETFs maintain identical expense ratios of 0.08% and deliver nearly 100% exposure to the health care sector, resulting in highly similar cost structures and thematic focus.
• FHLC offers greater diversification with approximately 330 holdings compared to XLV’s roughly 60 holdings, reducing concentration risk in top positions.
• Top holdings overlap significantly between the two ETFs, with Eli Lilly (LLY), Johnson & Johnson (JNJ), and AbbVie (ABBV) dominating both portfolios but weighted more heavily in XLV.
• FHLC’s inclusion of smaller companies may introduce modestly higher volatility during market cycles, whereas XLV’s large-cap bias tends to provide more stable liquidity and lower turnover.
• Both funds serve as core passive vehicles for health care exposure, differing primarily in market-cap breadth rather than active strategy or leverage.

Introduction

Investors seeking targeted health care exposure often compare Fidelity MSCI Health Care Index ETF (FHLC) and Health Care Select Sector SPDR ETF (XLV) because both deliver passive, low-cost access to the same broad sector. The two ETFs compete directly as alternatives within health care rather than representing entirely different strategies. FHLC emphasizes comprehensive market-cap coverage while XLV concentrates on established large-cap names, giving investors a clear choice between breadth and liquidity within an otherwise aligned investment objective.

Fidelity MSCI Health Care Index ETF (FHLC) Overview

FHLC tracks the MSCI USA IMI Health Care 25/50 Index, a market-capitalization-weighted benchmark that spans the entire U.S. health care sector. The ETF holds approximately 330 securities, capturing large-, mid-, and small-cap companies. Top holdings as of recent data include Eli Lilly (LLY) at roughly 13.3%, Johnson & Johnson (JNJ) at 8.8%, AbbVie (ABBV) at 6.5%, UnitedHealth Group (UNH) at 5.5%, and Merck (MRK) at 4.6%. Sector allocation is essentially 100% health care. FHLC charges an expense ratio of 0.08% and employs a fully passive, rules-based replication methodology with periodic rebalancing aligned to the index. Its distinguishing feature is broader diversification across market capitalizations compared with large-cap-only peers.

Health Care Select Sector SPDR ETF (XLV) Overview

XLV tracks the Health Care Select Sector Index, which comprises health care companies within the S&P 500. The fund typically holds around 60 large-cap securities. Recent top holdings feature Eli Lilly (LLY) at approximately 15.5%, Johnson & Johnson (JNJ) at 10.5%, AbbVie (ABBV) at 7.6%, UnitedHealth Group (UNH) at 6.4%, and Merck (MRK) at 5.5%. Allocation remains 100% within health care. XLV also maintains an expense ratio of 0.08% and follows a passive, market-cap-weighted approach with quarterly rebalancing to match its underlying index. Its primary characteristic is concentrated exposure to the largest, most liquid health care firms.

Industry and Thematic Backdrop

The U.S. health care sector continues to benefit from long-term demographic trends such as population aging and rising demand for pharmaceuticals, biotechnology, and medical devices. Innovation in areas including GLP-1 therapies and precision medicine has driven capital allocation toward leading companies. Regulatory developments around drug pricing and patent protections, along with evolving interest-rate expectations, influence sector performance across market cycles. Both ETFs remain exposed to these macro and policy factors without leverage or active security selection.

Performance and Positioning Comparison

Over recent weeks and months, both ETFs have reflected broader health care sector rotation tied to earnings results from large pharmaceutical and biotechnology firms. FHLC’s wider market-cap exposure can produce modestly different relative returns during periods when smaller health care companies outperform or underperform large caps. XLV’s concentration in S&P 500 names has historically delivered strong liquidity and tighter tracking during volatile cycles. Relative positioning hinges on investor preference for diversification breadth versus large-cap stability rather than on short-term price differentials.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Investors seeking data-driven insights on ETFs like FHLC or XLV may find the platform useful for ongoing research.

Tickeron AI Verdict

Based on observable structural factors, Tickeron’s AI would currently assign a modest probabilistic preference to FHLC for investors prioritizing diversification across market capitalizations and reduced single-stock concentration risk. XLV remains competitive for those emphasizing maximum liquidity and large-cap focus. The edge is marginal given identical expense ratios and high overlap in core holdings; final selection depends on an investor’s specific risk tolerance and allocation objectives.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations